Sana Biotechnology, Inc. Contracts & Agreements

Sixth Amendment to License Agreement by and between the Company and President and Fellows of Harvard College, dated as of August 28, 2024 (Filed With SEC on November 8, 2024)

Amendment No. 2 to Amended and Restated License Agreement by and between the Company and the University of Rochester, dated as of May 30, 2024 (Filed With SEC on November 8, 2024)

Separation, Transition Services, and General Release Agreement by and between the Company and Douglas E. Williams, dated April 15, 2024 (Filed With SEC on August 8, 2024)

Second Amendment to Exclusive License Agreement by and between the Company and The Regents of the University of California acting through the Technology Development Group of The... (Filed With SEC on August 8, 2024)

Amendment No. 4 to Option and License Agreement by and between the Company and Beam Therapeutics Inc., dated as of April 4, 2024 (Filed With SEC on May 8, 2024)

Amendment No. 1 to Amended and Restated Exclusive Patent License Agreement by and between the Company and Rochester, dated as of December 30, 2022 (Filed With SEC on February 29, 2024)

First Amendment to Exclusive License Agreement by and between the Company and The Regents acting through The Technology Development Group of UCLA, dated as of May 21, 2021 (Filed With SEC on February 29, 2024)

Change in Control Severance Plan and Summary Plan Description (Filed With SEC on February 29, 2024)

Form of Pre-Funded Warrant (Filed With SEC on February 8, 2024)

Underwriting Agreement, dated as of February 7, 2024, among Sana Biotechnology, Inc. and the Representatives (Filed With SEC on February 8, 2024)

Amendment No. 3 to Patents Sub-License Agreement by and between the Company and La Societe Pulsalys, dated as of July 31, 2023 (Filed With SEC on November 8, 2023)

Consulting Agreement by and between the Company and Sunil Agarwal, dated as of April 29, 2023 (Filed With SEC on May 8, 2023)

Amendment No. 3 to Option and License Agreement by and between the Company and Beam Therapeutics Inc., dated as of March 17, 2023 (Filed With SEC on May 8, 2023)

Offer Letter by and between the Company and Douglas E. Williams, dated as of April 8, 2023 (Filed With SEC on May 8, 2023)

Transition Agreement and Release by and between the Company and Sunil Agarwal, dated as of April 28, 2023 (Filed With SEC on May 8, 2023)

Amendment No. 2 to Non-Exclusive License and Development Agreement by and between the Company and FCDI, dated as of October 26, 2021 (Filed With SEC on March 16, 2023)

Amendment No. 1 to Non-Exclusive License and Development Agreement by and between the Company and FCDI, dated as of April 12, 2021 (Filed With SEC on March 16, 2023)

Fifth Amendment to License Agreement by and between the Company and Harvard, dated as of February 9, 2023 (Filed With SEC on March 16, 2023)

Non-Employee Director Compensation Program (Filed With SEC on March 16, 2023)

Amendment No. 10 to Exclusive Start-Up License Agreement by and between the Company and UW, dated as of October 30, 2021 (Filed With SEC on November 2, 2022)

Amendment No. 2 to Patents Sub-License Agreement by and between the Company and La Societe Pulsalys, dated as of March 9, 2022 (Filed With SEC on November 2, 2022)

Amendment No. 2 to Option and License Agreement by and between the Company and Beam Therapeutics Inc., dated as of July 19, 2022 (Filed With SEC on November 2, 2022)

Amendment No. 5 to Exclusive Start-Up License Agreement by and between the Company and University of Washington (UW), dated as of February 25, 2021 (Filed With SEC on November 2, 2022)

Amendment No. 6 to Exclusive Start-Up License Agreement by and between the Company and UW, dated as of March 11, 2021 (Filed With SEC on November 2, 2022)

Amendment No. 7 to Exclusive Start-Up License Agreement by and between the Company and UW, dated as of April 14, 2021 (Filed With SEC on November 2, 2022)

Amendment No. 9 to Exclusive Start-Up License Agreement by and between the Company and UW, dated as of September 9, 2021 (Filed With SEC on November 2, 2022)

Amendment No. 11 to Exclusive Start-Up License Agreement by and between the Company and UW, dated as of July 14, 2022 (Filed With SEC on November 2, 2022)

Offer Letter and Employment Agreement by and between the Company and Bernard Cassidy, dated as of September 8, 2022 (Filed With SEC on November 2, 2022)

Amendment No. 1 to the 2021 Employee Stock Purchase Plan, dated as of October 27, 2022 (Filed With SEC on November 2, 2022)

Amendment No. 8 to Exclusive Start-Up License Agreement by and between the Company and UW, dated as of July 20, 2021 (Filed With SEC on November 2, 2022)

Amendment No. 1 to Option and License Agreement, by and between the Company and Beam Therapeutics Inc., dated as of June 6, 2022 (Filed With SEC on August 4, 2022)

Lease Agreement by and between the Company and ARE-Seattle No., 39, LLC, dated as of June 1, 2022 (Filed With SEC on August 4, 2022)

Third Amendment to License Agreement by and between the Company and Harvard, dated as of May 20, 2021 (Filed With SEC on March 16, 2022)

Fourth Amendment to 2018 Equity Incentive Plan, dated as of December 8, 2021 (Filed With SEC on March 16, 2022)

First Amendment to 2021 Incentive Award Plan, dated as of December 8, 2021 (Filed With SEC on March 16, 2022)

Form of Stock Option Grant Notice and Stock Option Agreement under the 2021 Incentive Award Plan (Filed With SEC on March 16, 2022)

Non-Employee Director Compensation Program (Filed With SEC on March 16, 2022)

Fourth Amendment to License Agreement by and between the Company and Harvard, dated as of October 25, 2021 (Filed With SEC on March 16, 2022)

Patent License Agreement by and between the Company and the U.S. Department of Health and Human Services, as represented by The National Cancer Institution, an institute of the... (Filed With SEC on March 16, 2022)

2018 Equity Incentive Plan, as amended (Filed With SEC on November 8, 2021)

Option and License Agreement, effective October 15, 2021, by and between the Company and Beam Therapeutics Inc (Filed With SEC on November 8, 2021)

Lease Agreement, effective July 13, 2021, by and between the Company and Pacific Commons Owner, LP (Filed With SEC on August 4, 2021)

Third Amendment to Agreement and Plan of Merger dated March 22, 2021 by and between the registrant and Cobalt Biomedicine Inc (Filed With SEC on May 5, 2021)

Description of Securities Registered Pursuant to Section 12 of the Securities and Exchange Act of 1934, as amended (Filed With SEC on March 24, 2021)

Non-Exclusive License and Development Agreement by and between the Registrant and Fujifilm Cellular Dynamics, Inc., effective on February 1, 2021 (Filed With SEC on February 2, 2021)

Amendment No. 4 to Exclusive Start-Up License Agreement, effective on January 21, 2021 by and between the Registrant and UW (Filed With SEC on January 28, 2021)

Amendment No. 2 to Exclusive Start-Up License Agreement, effective on July 16, 2020, by and between Cytocardia and UW (Filed With SEC on January 28, 2021)

Form of Underwriting Agreement (Filed With SEC on January 28, 2021)

Form of Common Stock Certificate (Filed With SEC on January 28, 2021)

Form of Indemnification and Advancement Agreement for directors and officers (Filed With SEC on January 28, 2021)

2021 Incentive Award Plan (Filed With SEC on January 28, 2021)

Form of Stock Option Grant Notice and Stock Option Agreement under the 2021 Incentive Award Plan (Filed With SEC on January 28, 2021)

Form of Restricted Stock Award Grant Notice and Restricted Stock Award Agreement under the 2021 Incentive Award Plan (Filed With SEC on January 28, 2021)

Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement under the 2021 Incentive Award Plan (Filed With SEC on January 28, 2021)

Employee Stock Purchase Plan (Filed With SEC on January 28, 2021)

Non-Employee Director Compensation Program (Filed With SEC on January 28, 2021)

Patents Sub-License Agreement, dated August 16, 2018, by and between La Societe Pulsalys (Pulsalys) and Cobalt (Filed With SEC on January 13, 2021)

First Amendment to Agreement and Plan of Merger, dated as of January 29, 2019, by and among the Registrant, Merger Sub, Cobalt, and the Stockholders Representative (Filed With SEC on January 13, 2021)

First Amendment to License Agreement, dated as of February 14, 2019, by and between Flagship Innovations V and Cobalt (Filed With SEC on January 13, 2021)

License Agreement, effective as of February 17, 2016, by and between Flagship Pioneering Innovations V, Inc. (Flagship Innovations V) and Cobalt Biomedicine, Inc. (Cobalt) (Filed With SEC on January 13, 2021)

Offer Letter and Employment Agreement by and between the Registrant and James J. MacDonald, dated as of October 2, 2018 (Filed With SEC on January 13, 2021)

Offer Letter and Employment Agreement by and between the Registrant and Nathan Hardy, dated as of October 8, 2018 (Filed With SEC on January 13, 2021)

Offer Letter and Employment Agreement by and between the Registrant and Christian Hordo, dated as of November 10, 2018 (Filed With SEC on January 13, 2021)

Offer Letter and Employment Agreement by and between the Registrant and Richard Mulligan, Ph.D., dated as of April 23, 2020 (Filed With SEC on January 13, 2021)

Offer Letter and Employment Agreement by and between the Registrant and Steven D. Harr, M.D., dated as of September 27, 2018 (Filed With SEC on January 13, 2021)

Form of Stock Option Agreement under 2018 Equity Incentive Plan (Filed With SEC on January 13, 2021)

Second Amendment to 2018 Equity Incentive Plan, dated as of December 4, 2020 (Filed With SEC on January 13, 2021)

First Amendment to 2018 Equity Incentive Plan, dated as of November 9, 2020 (Filed With SEC on January 13, 2021)

2018 Equity Incentive Plan, as amended (Filed With SEC on January 13, 2021)

Amended and Restated Investors Rights Agreement, dated February 13, 2019, by and among the Registrant and the investors listed therein (Filed With SEC on January 13, 2021)

Stock Purchase Agreement, dated as of September 10, 2020, by and among the Registrant, Oscine Holdings, LLC (Oscine), and each of the members of Oscine (Filed With SEC on January 13, 2021)

Stock Purchase Agreement, dated as of November 12, 2019, by and among the Registrant, Cytocardia, Inc. (Cytocardia), each of the stockholders of Cytocardia, and Scott Thies, as... (Filed With SEC on January 13, 2021)

Second Amendment to Agreement and Plan of Merger, dated as of February 8, 2019, by and among the Registrant, Merger Sub, Cobalt, and the Stockholders Representative (Filed With SEC on January 13, 2021)

Agreement and Plan of Merger, dated as of December 20, 2018, by and among the Registrant, Sana Biotechnology IV, Inc. (Merger Sub), Cobalt Biomedicine, Inc. (Cobalt), and... (Filed With SEC on January 13, 2021)

Exclusive License Agreement, effective on September 1, 2020, by and between the Registrant and Washington University (Filed With SEC on January 13, 2021)

Offer Letter and Employment Agreement by and between the Registrant and Sunil Agarwal, M.D., dated as of May 20, 2019 (Filed With SEC on January 13, 2021)

Assignment of Exclusive Start-Up License Agreement, effective on November 11, 2020, by and among UW, Cytocardia and the Registrant (Filed With SEC on January 13, 2021)

Amendment No. 1 to Exclusive Start-Up License Agreement, effective on November 6, 2019, by and between Cytocardia and UW (Filed With SEC on January 13, 2021)

Exclusive Start-Up License Agreement, effective on October 9, 2018, by and between Cytocardia, Inc. (Cytocardia) and the University of Washington, acting through UW CoMotion (UW) (Filed With SEC on January 13, 2021)

Amendment No. 2 to Seed Bank Supply Agreement, dated as of January 6, 2021, by and among the Registrant, Oscine Affiliate, and Hadasit (Filed With SEC on January 13, 2021)

Amendment No. 1 to Seed Bank Supply Agreement, dated as of July 9, 2018, by and among the Registrant, Oscine Affiliate, and Hadasit (Filed With SEC on January 13, 2021)

Seed Bank Supply Agreement, dated as of July 9, 2018, by and between Oscine Therapeutics (U.S.) Inc. (Oscine Affiliate) and Hadasit Medical Research Services and Development Ltd.... (Filed With SEC on January 13, 2021)

Amended and Restated Exclusive Patent License Agreement, dated September 10, 2020, by and among the Registrant, Oscine Corp., and University of Rochester (Filed With SEC on January 13, 2021)

Amendment No. 1 to Patents Sub-License Agreement, dated May 26, 2020, by and between Pulsalys and Cobalt (Filed With SEC on January 13, 2021)

Exclusive License Agreement, effective on November 14, 2019, by and between the Registrant and Washington University (Filed With SEC on January 13, 2021)

Amendment No. 1 to Exclusive License Agreement, effective on December 3, 2020, by and between the Registrant and UCSF (Filed With SEC on January 13, 2021)

Exclusive License Agreement, effective on January 2, 2019, by and between the Registrant and The Regents, acting through its Office of Technology Management, University of... (Filed With SEC on January 13, 2021)

Amendment No. 2 to License Agreement, dated as of December 15, 2020, by and between the Registrant and Harvard (Filed With SEC on January 13, 2021)

Amendment No. 1 to License Agreement, dated as of June 10, 2019, by and between the Registrant and Harvard (Filed With SEC on January 13, 2021)

License Agreement, dated as of March 19, 2019, by and between the Registrant and President and Fellows of Harvard College (Harvard) (Filed With SEC on January 13, 2021)

Exclusive License Agreement, dated March 22, 2019, by and between the Registrant and the Regents of the University of California (The Regents) acting through the Technology... (Filed With SEC on January 13, 2021)

Category

Industry

Companies

Contracts

Sana Biotechnology, Inc. Contracts & Agreements